Abatacept restores dysregulated transcriptomic and proteomic profile in disorders of CTLA-4 insufficiency
Journal of Allergy and Clinical Immunology · 2025-12 · 156 (6) · 1725-1742
DOI: 10.1016/j.jaci.2025.08.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-12. Verfasst von Mehmet Cihangir Catak und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Turkey; Istanbul Jeffrey Modell Diagnostic and Res…. Hauptthemen laut MEDLINE: Abatacept, CTLA-4 Antigen, Transcriptome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Sidra Medicine, Jeffrey Modell Foundation, Marmara Universitesi.
Abstract (Originalsprache)
BACKGROUND: Lipopolysaccharide-responsive beige-like anchor (LRBA) deficiency and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) insufficiency are rare primary immune dysregulation disorders. Both conditions result from impaired maintenance of CTLA-4, a critical inhibitory checkpoint molecule. Despite the known benefits of abatacept (a CTLA-4-Ig fusion protein) treatment, its precise immunologic effects remain unclear. OBJECTIVE: We comprehensively investigated the effect of abatacept therapy on patients with LRBA deficiency and CTLA-4 insufficiency using an integrative multiomics approach. METHODS: The study combined longitudinal flow cytometry, targeted and single-cell transcriptomics, and plasma proteomics in patients receiving abatacept treatment. RESULTS: Abatacept treatment increased thymic output and expansion of naive T and B cells while reducing memory T-cell subsets, CD4+ T-cell cytokine production, and CD21low B cells. Multimodal transcriptomic and proteomic analyses revealed previously unrecognized immunopathogenic mechanisms, including increased CD28 and T-cell receptor signaling as well as compensatory upregulation of inhibitory checkpoint proteins (LAG3, TIGIT, ADORA2A, VSIR, HAVCR2) in response to CTLA-4 insufficiency. Proteomic profiling confirmed the upregulation of inflammatory mediators, including CHI3L1, CXCL13, and CSF1. Most of these transcriptomic and proteomic abnormalities were reversed after abatacept therapy; notably, gene signatures derived from lymphocytes exhibited greater normalization than those associated with myeloid cells. Furthermore, identified shared and disease-specific molecular signatures distinguished LRBA-deficient patients from those with CTLA-4 insufficiency, revealing more severe immune dysregulation in LRBA deficiency. Single-cell RNA sequencing validated the reversal of checkpoint dysregulation and the expression of inflammation-related genes across lymphoid and myeloid lineages. CONCLUSION: Abatacept effectively corrects key immune circuits in both diseases. This integrative systems-level approach offers new mechanisms and therapeutic targets, supporting personalized intervention strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Turkey; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey; The Isi…
- Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.
- GENALYSE Genetic & Reporting Ltd, Istanbul, Turkey.
- College of Science and Engineering, Flinders University, Bedford Park, Adelaide, Australia.
- Institute of Child Health, Hacettepe University, Ankara, Turkey; Can Sucak, Research Laboratory for Translational Immunology, Hacettepe University, Ankara, Turkey.
- Division of Translational Medicine, Research Branch, Sidra Medicine, Doha, Qatar.
Förderung
- Sidra Medicine
- Jeffrey Modell Foundation
- Marmara Universitesi
Zitieren
APA
Catak, M. C., Surucu, N., Bayram Catak, F., Kara, A., Cildir, S., Babayeva, R., Kayaoglu, B., Bulutoglu, A., Erman, B., Karakus, I. S., Al-Shaibi, A., Hubrack, S., Karabiber, E., Celik, F. C., Akgun, G., Baser, D., Bilgic Eltan, S., Sefer, A. P., Bozkurt, S., …, & Baris, S. (2025). Abatacept restores dysregulated transcriptomic and proteomic profile in disorders of CTLA-4 insufficiency. Journal of Allergy and Clinical Immunology, 156(6), 1725-1742. https://doi.org/10.1016/j.jaci.2025.08.027
Vancouver
Catak MC, Surucu N, Bayram Catak F, Kara A, Cildir S, Babayeva R, et al. Abatacept restores dysregulated transcriptomic and proteomic profile in disorders of CTLA-4 insufficiency. Journal of Allergy and Clinical Immunology. 2025;156(6):1725-1742. doi:10.1016/j.jaci.2025.08.027
BibTeX
@article{Catak2025,
author = {Catak, Mehmet Cihangir and Surucu, Naz and Bayram Catak, Feyza and Kara, Altan and Cildir, Selin and Babayeva, Royala and Kayaoglu, Basak and Bulutoglu, Alper and Erman, Baran and Karakus, Ibrahim Serhat and Al-Shaibi, Ahmad and Hubrack, Satanay and Karabiber, Esra and Celik, Figen Celebi and Akgun, Gamze and Baser, Dilek and Bilgic Eltan, Sevgi and Sefer, Asena Pinar and Bozkurt, Selcen and Ozturk, Necmiye and Kiykim, Ayca and Aydogmus, Cigdem and Genel, Ferah and Gulez, Nesrin and Yucel, Esra and Yildiran, Alisan and Metin, Ayse and Karakoc-Aydiner, Elif and Ozen, Ahmet and Gursel, Mayda and Cildir, Gökhan and Lo, Bernice and Baris, Safa},
title = {Abatacept restores dysregulated transcriptomic and proteomic profile in disorders of CTLA-4 insufficiency},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
volume = {156},
number = {6},
pages = {1725--1742},
doi = {10.1016/j.jaci.2025.08.027}
}
EUVIMED